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Abstract
Angiogenesis and vascular regression are critical for the female ovulatory cycle. They enable progression and regression of follicular
development, and corpora lutea formation and regression. Angiogenesis in the ovary occurs under the control of the vascular endothelial
growth factor-A (VEGFA) family of proteins, which are generated as both pro-(VEGF165) and anti(VEGF165b)-angiogenic isoforms by
alternative splicing. To determine the role of the VEGF165b isoforms in the ovulatory cycle, we measured VEGF165b expression in
marmoset ovaries by immunohistochemistry and ELISA, and used transgenic mice over-expressing VEGF165b in the ovary. VEGF165b
was expressed in the marmoset ovaries in granulosa cells and theca, and the balance of VEGF165b:VEGF165 was regulated during
luteogenesis. Mice over-expressing VEGF165b in the ovary were less fertile than wild-type littermates, had reduced secondaryand tertiary
follicles after mating, increased atretic follicles, fewer corpora lutea and generated fewer embryos in the oviduct after mating, and these
were more likely not to retain the corona radiata. These results indicate that the balance of VEGFA isoforms controls follicle progression
and luteogenesis, and that control of isoform expression may regulate fertility in mammals, including in primates.
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Introduction
Formation of new blood vessels (angiogenesis) has a
critical role in the female reproductive system, by
affecting, for example, the cyclic changes that occur in
the ovary during the ovulatory cycle (Charnock-Jones
et al. 1993), ovarian follicular development (Yan et al.
1993), corpus luteum (CL) and endometrium formation
(Kamat et al. 1995), and remodelling of mammary gland
to enable lactation (Pepper et al. 2000). Speciﬁcally,
studies in which the principal angiogenic factor, vascular
endothelial growth factor-A (VEGFA), was inhibited
in vivo in the mouse, marmoset or macaque established
that angiogenesis is required throughout follicular
development, as ovarian follicles progress during the
cycle (Zimmermann et al. 2001, 2002, 2003, Wulff
et al. 2002), after ovulation for the formation of the CL
(Wulff et al. 2001, 2002, Zimmermann et al. 2001, 2002)
and for normal endometrial development (Fan et al.
2008, Fraser et al. 2008).
VEGFA expression has been localised within the
different ovarian and endometrial compartments using
immunohistochemistry, PCR and in situ hybridisation
(Charnock-Jones et al. 1993, Shweiki et al.1 9 9 3 ).
However, VEGF is alternatively spliced to generate
many isoforms that differ in the heparin-binding activity
and receptor activation potential. Alternative splicing
of exons 6 and 7 generates different-length isoforms (e.g.
VEGF121, VEGF165, VEGF189) and alternative splice site
selection in exon 8 generates two families of isoforms,
the pro-angiogenic VEGFxxx family (where xxx is the
number of amino acids in the peptide monomer, e.g.
VEGF165) and the anti-angiogenic VEGFxxxb family
(e.g. VEGF121b, VEGF165b; Harper & Bates 2008). The
two families differ in the choice of splice site in the
terminal exon, exon 8, resulting in differing C termini,
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commercial antibodies and probes do not distinguish
between the VEGFxxxb and VEGFxxx families, and even
fewer between the isoforms within each family. It has
previously been shown that VEGF165b, the most widely
studied form of the VEGFxxxb family, inhibits VEGF165-
mediated angiogenesis in the rabbit cornea, chick
chorioallantoic membrane, rat mesentery and mouse
dorsal skin chamber (Cebe Suarez et al. 2006), and
during physiological angiogenesis in the mammary fat
pad (Qiu et al. 2008). It also inhibits pathological
angiogenesis in the retina due to ischaemia (Magnussen
et al. 2010) or inﬂammation (Hua et al. 2010), and in
cancer (Rennel et al. 2008a, 2008b). Switching the
splice site from proximal, VEGF165 encoding, to distal,
VEGF165b encoding, results in reduced angiogenesis in
cancer (Varey et al. 2008) and the retina (Nowak et al.
2010). Analysis of VEGF165b expression in multiple
human tissues has shown that the levels of VEGF165b
vary substantially from !15% of total VEGF in placenta
(Bates et al. 2006), to O95% in normal human colon
(Varey et al. 2008), and that this ratio varies greatly
between tissues (Woolard et al. 2009) in physiological
and pathological conditions (Schumacher et al. 2007),
including those where pathological angiogenesis is
occurring (Pritchard-Jones et al. 2007).
As VEGFA has a critical role in ovarian angiogenesis,
we investigated the expression pattern of VEGFxxxbi n
the ovary of the marmoset monkey, a species in which
the contribution of VEGF to ovarian function has been
comprehensively studied (Fraser & Duncan 2009), and
examined whether expression levels are altered during
the ovulatory cycle. To investigate the effects of
manipulation of VEGF165b in the ovary, we used a
transgenic (TG) mouse that over-expresses VEGF165b.
We show that VEGFxxxb is expressed in primate ovaries,
is downregulated during CL formation, and that over-
expression of VEGF165b in mice reduces fertility by
inhibiting follicular development and CL formation.
Results
VEGF165b is expressed in primate ovaries
Sections of marmoset ovaries were stained for VEGFxxxb
using an antibody raised against the nine amino acid C
terminus of human VEGF165b( Woolard et al.2 0 0 4 ;
Fig. 1A). Immunohistochemical analysis showed clear
VEGF165b expression in the theca layer of follicles and in
the granulosa cell layer of primaryand secondary follicles
(Fig. 1A), while it was absent from the granulosa cells of
tertiary follicles. Localisation was also present in the CL.
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Figure 1 Expression of VEGF165b in primate
ovary. (A) Endogenous expression of VEGF165b
in marmoset ovary using an anti-VEGF165b
speciﬁc antibody. TI, theca interna; GC, granu-
losa cells; C, capillary; O, oocyte; CL, Corpus
luteum; 28A, secondary antral follicle; 18,
primary; A, antral; P, primordial. (B) ELISA for
VEGFxxxb and total VEGF on protein extracted
from marmoset ovary. (C) Percentage of VEGF
that is VEGFxxxb in marmoset ovary. **P!0.01
t-test with Welch’s correction. nZ7 total.
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VEGF and VEGFxxxb levels were measured using either
an ELISA for total VEGF or one speciﬁc for the VEGFxxxb
isoforms (Fig. 1B and C). Protein quantiﬁcation showed
that in ovaries that contained no corpora lutea, the
measured VEGFxxxb levels were similar to the total VEGF
levels (Fig. 1B), suggesting that the majority of VEGF in
these quiescent ovaries is VEGF165b (not different from
100%). In contrast, in ovaries in which corpora lutea
were found there was less VEGF165b than total VEGF,
and the percentage of total VEGF attributable to
VEGF165b was signiﬁcantly smaller, 65G11% (P!0.05
compared to no CL, Fig. 1C, nZ7).
VEGF165b over-expression in the ovary reduces fertility
in TG mice
We generated TG mice over-expressing human VEGF165b
under control of the mouse mammary tumour virus
(MMTV) promoter (Qiu et al. 2008). These mice showed
strongexpressionofVEGF165bmRNAintheovaryofvirgin
animals, and weak expression in the uterus (Fig. 2A).
Immunohistochemical analysis of mouse ovaries using a
human speciﬁc anti-VEGF antibody showed strong
expression of VEGF in the TG ovaries, but not in the
wild-type (WT) ovaries (Fig. 2B). When TG females were
mated with WT mice, the numbers of pups born to these
mothers was signiﬁcantly lower per litter (3.3G0.4
comparedwith5.9G0.7intheWTlittermates).Incontrast,
WTfemalesmatedwithTG males producednormal-sized
litters (6.1G0.7pupsperlitter, Fig.2C). To help determine
whether the reduction in pup number was due to reduced
ovulatory function or due to developmental defects, we
determined pups birth weight and their genotype. Pups
were born at a Mendelian frequency (50% of offspring
were TG), and with normal birthweight (Supplementary
Figure 1, see section on supplementary data given at the
end of this article) indicating no offspring-dependent
developmental defect. To determine whether ovulation
was normal, we opened the oviducts of 13 TG and 9 WT
females 0.5 days post coitus (dpc) and collected the
embryos. The TG mothers had 82G6% of the number of
VEGF165b
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Figure 2 Over-expression of VEGF165b in mouse ovary
reduces litter size. (A) Mouse ovaries from wild-type or
transgenic MMTV-VEGF165b mice as shown were taken
and RNA was extracted. RT-PCR was performed using
primers speciﬁc for the human transgene. (B) Mouse
tissues were ﬁxed and stained using an anti-human VEGF
antibody that detects all human isoforms but does not
detect mouse VEGF. (C) Measurement of litter size in 10
transgenic (TG) or wild-type (WT) females mated to wild-
type males. **P!0.01 paired t-test, nZ10 compared
with littermate control. Wild-type females were also
mated to TG males. NS, not signiﬁcant compared with
wild-type (unpaired t-test).
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Figure 3 Changes in the embryos of the TG female mice over-expressing VEGF165b. (A) Mice were culled at 0.5 dpc and embryos were collected
fromtheoviducts.VEGF165bover-expressionledtoareducednumberofembryos intheoviducts.
†P!0.05, Wilcoxonsigned-ranktest.(B)Imagesof
embryos showing that those from TG females lack the corona radiata (CR) structure.
#P!0.05 Fisher’s exact test. (C) Ovaries from these mice were
ﬁxed, sectioned through and stained with H&E to count follicles. P!0.001 one-way ANOVA, *P!0.05, **P!0.01, ***P!0.001 Bonferroni
post-hoc test. nZ6 per group. (D) The number of tertiary follicles as a percentage of secondary follicles was determined. **P!0.01 Mann–Whitney
t-test. (E) Ovaries were stained with cleaved caspase-3 antibody and the number of positive (apoptotic cells) was determined. (F) The proportion of
follicles with between 1 and 10 and O10 positive cells were compared (
###P!0.001, Fisher’s exact test on follicle frequency, nZ6 animals per
group, 274 follicles WT, 234 TG) (G). Ovaries taken at 0.5 dpc were ﬁxed and stained using isolectin B4 to detect endothelial cells, and
counterstained with Hoechst. Images offollicles from WTand TG female ovaries stained with IB4 to show MVD. (H) Microvessels were counted and
expressed as microvessel covering area per unit perimeter of the follicle. *P!0.05, Mann–Whitney t-test.
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Fig. 3A). Moreover, strikingly, the embryos in the oviducts
from the TG lacked adherent corona radiata in 60% of the
mothers (Fig. 3B). Embryos were cultured for 4 days, and
survival was measured by determining the rate of
progression to blastocyst stage. There was no difference
in the percentage of embryos reaching blastocyst stage
when comparing embryos from TG and WT mothers
(Supplementary Figure 2, see section on supplementary
datagivenattheendofthisarticle).Thissuggestedadefect
in folliculogenesis rather than developmental defects.
We, therefore, collected ovaries from six TG and six WT
female mice at 0.5 dpc and sectioned through the ovaries
to determine follicle number. There was no statistical
difference in the total number of follicular elements
(follicles and corpora lutea) between WT (12G2.6 per
section) and TG (8.6G1.3 per section, PO0.1 t-test) mice
sampled per section. However, as shown in Fig. 3C, there
was a signiﬁcant reduction in secondary, tertiary and
mature follicle numbers in the TG compared with the WT
mice. There was no statistical difference in primordial or
primaryfolliclespersectionbetweenWTandTGanimals.
Furthermore, there was a signiﬁcant reduction in the
percentage of tertiary to secondary follicles (Fig. 3D),
suggesting not onlya reduction in follicular development,
but also a further defect in follicular maturation to the
tertiarystage.Interestingly,thereweremoreatreticfollicles
in the TG mice than those in the WT. The mechanisms for
increased atresia were investigated by staining for
apoptotic cells in the ovaries (Fig. 3E). Activated caspase-
3-positivecellshavebeenusedasanindicatorofearlyand
late atresia (Utsunomiya et al.2 0 0 8 ). Atretic follicles with
fewer than 10 cleaved caspase-3-positive cells have
previously been regarded as early atresia and those with
more than 10 as late atresia. There was no increase in the
proportion of follicles in early atresia in TG mice (11%)
compared with WT (13%), but a statistically signiﬁcant
increase in the proportion of late atretic follicles in TG
(40%, nZ6m i c e ;P!0.01, Fisher’s exact test) compared
with WT (24%, nZ6, Fig. 3F). To determine whether this
reduction was associated with reduced vascular density
around follicles, we stained the ovaries with isolectin B4,
and determined the number of vessels covering the area
(Fig.3G).Therewasasigniﬁcantreductioninbloodvessels
surrounding follicles from TG mothers (Fig. 3H, P!0.05).
Angiogenesis is also required for corpora lutea
formation. As VEGF165b levels are reduced in marmoset
ovaries containing CL, it is possible that a down-
regulation occurs, to allow the intense angiogenesis
that takes place in this organ. We, therefore, measured
the size, number and vascularity of the CL in the largest
cross section of ovaries from sevenTG and ﬁve WT mice,
to determine whether VEGF165b over-expression inhibits
CL formation. The number of CL per ovary was reduced
in TG animals, consistent with reduced follicular
development (Fig. 4A). In addition, the size of the CL
was also reduced (Fig. 4B) from 0.82G0.19 mm
2 in the
WT to 0.23G0.08 mm
2 in the TG (P!0.01, t-test). The
proportion of CL with both between 1 and 10 cleaved
caspase-3-positive cells (early CL regression) was also
increased in TG (31% compared with 18% in WT) and
with more than 10 cleaved caspase-3-positive cells (26%
compared with 1%, Fig. 4C). These results indicate that
regression of the CL is more rapid in the TG mice.
Figure 4D shows microvascular (red) and pericyte
(green) staining in the CL. Both the microvascular
density (MVD; Fig. 4E) and the mean pericyte coverage
(Fig. 4F) were reduced in the TG mice (both P values
!0.05, t-test with Welch’s correction).
To determine whether the reduced follicular develop-
ment resulted in, or was associated with, altered ovarian
cyclicity, we staged mice by daily vaginal smearing
(Fig. 5A). Figure 5B shows that the TG mice had a 23%
increase in ovulatory cycle length (6.0G0.25 days, nZ6)
compared with WT littermates (4.85G0.26 days, nZ7,
PZ0.022, Mann–Whitney U-test). Closer examination
showed that the increase in the length of the estrous cycle
was due to extension of estrus (Fig. 5C) from 1.6G0.24 to
2.5G0.19 days (P!0.05, Mann–Whitney U-test).
Discussion
Follicular development in the ovary has been shown to
be dependent on angiogenesis, in particular on blood
vessel growth driven by the angiogenic isoforms of
VEGF. VEGF165 is upregulated in the follicle during
development (Ravindranath et al. 1992, Shweiki et al.
1993, Taylor & Mueller 2004) and inhibition of VEGF by
administration of VEGF-TRAP (Wulff et al.2 0 0 2 ),
antibodies to VEGF (Zimmermann et al. 2001)a n d
VEGFR tyrosine kinase inhibitors (McFee et al. 2009)
results in inhibition of follicular development. However,
all these inhibitors target both the pro-angiogenic and
the anti-angiogenic isoforms of VEGF (Varey et al. 2008).
VEGF165b has been shown to be anti-angiogenic in both
pathological circumstances, such as ischemic retino-
pathy (Konopatskaya et al. 2006), models of age-related
macular degeneration (Hua et al. 2010), prostate (Rennel
et al. 2008a), lung (Merdzhanova et al. 2010), renal
(Rennel et al. 2008a), skin (Pritchard-Jones et al. 2007)
and colon (Varey et al.2 0 0 8 )c a n c e r s ,a n di n
physiological angiogenesis including gonadogenesis
(Artac et al. 2009) and mammary gland formation (Qiu
et al. 2008). The results shown here indicate that the
regulation of follicular development and hence fertility
are under control of differential splicing of VEGF. We
show that VEGF165b is localised within different cell
types in the marmoset ovary and levels decrease in
ovaries containing corpora lutea. Crucially, the over-
expression of VEGF165b in the mouse ovary, driven by
the MMTV promoter, demonstrated a functional role for
this isoform, causing delayed follicular and corpus luteal
development that contributed to a fertility defect in these
mice. The MMTV promoter drives expression in tissues
VEGF165b results in subfertility 505
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Figure 4 Over-expression of VEGF165b in the mouse ovary results in changes in the corpus luteum (CL). Ovaries collected from mice at 0.5 dpc were
ﬁxed and stained by H&E to investigate CL structure. (A) The number of CL in the largest cross section of each ovary was counted. *P!0.05, t-test.
(B) The total size of the CL in the largest cross section of each ovary was measured with ImageJ. *P!0.05, t-test. (C) Ovaries stained for cleaved
caspase-3 were analysed for corpus luteum staining in WT (i) and TG (ii). Numbers of CL were counted (iii) according to the proportion with 1–10
(early regression) and O10 cleavedcaspase-3-positive cells (late regression;
##P!0.01,
###P!0.001, Fisher’s exact test on CL frequency). nZ6 mice
per group, 90 CL in WT, 45 in TG). (D) Ovaries collected from mice at 0.5 dpc were ﬁxed and stained for microvessels using isolectin B4 (red) and
pericytes with anti-NG2 antibody (green). (E) Blood vessel density was counted and expressed as microvascular density (microvessel covering area
per mm
2 of CL). (F) Pericytes covering area per unit area of CL were counted.,
†P!0.05, t-test with Welch’s correction.
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progesterone (Otten et al. 1988). It is therefore expressed
in a variety of tissues during pregnancy and the ovarian
cycle, but the strongest expression is in the mammary
gland and the ovary in healthy mice (Wang & Greenwald
1993, Wagner et al. 2001).
From the results described above it appears that VEGF-
mediatedangiogenesis,inhibitedbyVEGF165bexpression,
is important for multiple components of the ovulatory
cycle. However, we did not discern an alteration in the
total number offollicles in these mice, indicating that any
effect of VEGF165b over-expression on oogenesis was not
detectable. It is the maturation of the follicle from primary
to secondary and to mature follicles that was inhibited by
the anti-angiogenic VEGF165b isoform over-expression, as
it is by VEGF inhibition (Zimmermann et al. 2003).
Importantly, we show here that the quality of the
progression is also inhibited, as the relationships between
the cumulus cells and the ovum appear to be disrupted,
resulting in release of an ovum lacking the cumulus
cell–oocytecomplex.Thepercentreductioninembryosin
the oviduct was not as great as the reduction in pup
number,suggestingthattherewasareductionintheability
of the embryos to implant in the uterus, in addition to
the reduction in embryos released. However, culture of
the embryos did not show anyevidence of developmental
defects in the embryos themselves, which together with
thenormal birthweightindicatethatthereduction inlitter
size is dependent on ovarian function.
Theincreaseinthelengthoftheestrous cycle,duetoan
increaseinthelengthofestrus,couldbearesultof,orlead
to, the delay in follicular development and defective CL
formation as has been shown when VEGFA is inhibited
(Fraser & Duncan 2009). Normally, the breakdown of the
basement membrane in the mature follicle results from
intense invasive angiogenesis across the theca interna that
is stimulated by an increase in VEGF165 expression by the
granulosa cells (Shweiki et al.1 9 9 3 ). The over-expression
of VEGF165b in the granulosa cells driven by the MMTV
promoter appears to be able to delay this vessel growth
with resulting reduction in the size of the CL. This is likely
to affect steroid production by the CL (Fraser et al. 2000),
but theimpact ofVEGF165b onprogesterone secretion has
yet to be determined.
Generationofthedifferentvariants ofVEGFresultsfrom
a process of alternative splicing that is tightly regulated in
normal conditions. Splice site selection is normally under
the control of a co-ordinated and regulated set of splice
factors,includingSRSF6(SRp55;Nowaketal.20 08 ),ASF/
SF2 (Nowak et al. 2010) and SC35 (Merdzhanova et al.
2010), which themselves are regulated by kinases such as
SRPK1 (Nowak et al.2 0 1 0 ). Very little is known about
the regulation of splice factors in the ovary, but the results
of the present study add to ﬁndings of other mRNAs that
are alternatively spliced in the ovary (e.g. LH receptor,
Mandai et al. 1997;F G F R 2 ,Parrott & Skinner 1998;
FSHR,Kraaijetal.1998andoestrogenreceptor,Chuetal.
2000) to suggest that regulation of ovarian function may
be controlled not only by regulation of gene transcription,
but also by regulation of alternative splicing.
Inconclusion,weshowthatalternativesplicingofVEGF
occurs in the primate ovary, and can regulate ovarian
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Figure 5 VEGF165b over-expression alters estrous
cycling. Estrus cycle was determined in MMTV-
VEGF165b transgenic mice, expressing VEGF165b in the
ovary, and littermate sisters, by composition of cells in
vaginal smears. Arrow, neutrophils; arrow head,
parabasal cells; curved arrow, intermediate cells and
*corniﬁed superﬁcial cells. (B) The TG mice had a
signiﬁcantly longer cycle time than the littermate
controls. (C) Determination of the lengths of the
cycles of each mice showed that estrus was longer bya
day in the TG compared with WT mice. *P!0.05,
Mann–Whitney U-test.
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intriguingpossibilitythat,inhumans,thebalanceofpro-vs
anti-angiogenic isoforms may regulate follicular develop-
ment, menstrual cycle length, and ultimately, fertility.
Materials and Methods
Animal maintenance: mice
The TG MMTV-VEGF165b (TG) line was generated on C57BL6!
CBA/CA background and back-crossed with C57BL6 mice as
described (Qiu et al.2 0 0 8 ). All experiments were carried out in
accordance with the UK Animals (Scientiﬁc Procedures) Act,
1986, and associated guidelines and with approval of the
University of Bristol Ethical Review Panel. These animals have
three copies of the MMTV-VEGF165b construct (Qiu et al.2 0 0 8 ).
For ovaryexperiments, 2- to 4-month-old F5–7 generation female
TG mice and WT littermate controls were used. For experiments
intheoviductandovary,TGorWTfemaleswerematedwithWT
malemice.Onceplugged,femalemicewereculledandoviducts
and ovary were dissected.
Marmoset tissue
Immunohistochemical localisation of VEGF165b was carried
out on ovaries obtained from normal adult marmoset monkeys
(Callithrix jacchus), which had been ﬁxed in neutral buffered
formalin and stored in parafﬁn blocks, having been generated
from experiments described previously (Duncan et al. 2008).
Two pairs of ovaries from the mid-follicular and mid-luteal
phase of the ovulatory cycle were used. For measurement of
levels of VEGF and VEGFxxxb within the marmoset ovary,
ovaries were obtained from adult marmosets being killed as a
result of health problems not related to the reproductive
system. Four marmosets were sedated and killed as described
previously (Wulff et al. 2002). Their ovaries were removed,
weighed and rapidly frozen in dry ice before being stored at
K70 8C until required. Four of the ovaries contained follicles,
while four consisted predominantly luteal tissue.
RT-PCR
Brieﬂy, total RNA was isolated with TRIzol (Invitrogen)
extraction and DNase I (Invitrogen) was digested as per the
manufacturer’s instructions to prevent gDNA contamination.
DNase-treated RNA (1 mg) was reverse transcribed into cDNA
with avian myeloblastosis virus (AMV) reverse transcriptase
using method described by the manufacturer (Promega). Both
cDNA and RNA treated with DNase I were subjected to PCR
with forward primer 50-ACA AGA TCC GCA GAC GTG TA-30
and reverse primer 50-ACAGAT GGC TGG CAA CTAGA-30 for
transgene detection. PCR ampliﬁcation was initiated at 94 8C
for 4 min, 35 cycles of 94 8C for 30 s, 50 8C for 30 s and 72 8C
for30 s, followedbyﬁnal extension at 72 8C for 10 min. A band
at 199 bp indicated VEGF165b transgene expression.
For mouse b-actin control, forward primer 50-AGC CAT GTA
CGT AGC CAT CC-30 and reverse primer 50-CTC TCA GCT
GTG GTG GTG AA-30 give a 228 bp PCR product, after
ampliﬁcation under the same cycle conditions as for transgene.
ELISA of VEGFxxxb
Tissue protein lysate was prepared from seven marmoset
ovaries in RIPA buffer. Protein concentration was determined
by Bio-Rad assay (Bio-Rad) and the amount of VEGF165b was
determined by ELISA as previously described (Varey et al.
2008) with a speciﬁc detection antibody against VEGFxxxb
isoforms with the operator masked to luteal content.
Brieﬂy, 0.08 mg goat anti-VEGF polyclonal IgG (AF293-NA;
R&D Systems, Abingdon, UK) diluted in 1!PBS (pH 7.4) was
adsorbed onto each well of a 96-well plate (Immulon 2HB;
Thermo Life Sciences, Basingstoke, UK) overnight at room
temperature. The plate was washed three times between each
step with 1!PBS–Tween (0.05%). After blocking with 100 mlof
5% BSA in PBS for 1 h at 37 8C, 100 ml recombinant human
VEGF165b (R&D Systems) diluted in 1% BSA in PBS (ranging
from 62.5 pg/ml to 4 ng/ml) or protein samples was added to
each well. After incubation for 1 h at 37 8C with shaking and
three washes, 100 ml mouse monoclonal anti-VEGFxxxb bioti-
nylated IgG (clone 264610/1; R&D Systems) at 0.4 mg/ml was
added to each well, and the plate was left for 1 h at 37 8C with
shaking. Streptavidin–HRP (100 ml; R&D Systems) at 1:200
dilution in 1% BSA in PBS wasadded, the plate wasleft at room
temperature for 20 min and 100 ml/well O-phenylenediamine
dihydrochloride solution (substrate reagent pack DY-999; R&D
Systems) was added, protected from light and incubated for
20 min at room temperature. The reaction was stopped with
50 ml/well 1 M H2SO4, and absorbance was read immediately
in the Opsys MR 96 well plate reader (Dynex Technologies,
Chantilly, VA, USA) at 492 nm, with control reading at 460 nm.
ELISA of pan-VEGF
Pan-VEGF detection was followed with the manufacturer’s
suggestion (Duoset human VEGF from R&D, cat. no. DY293).
Capture antibody (0.08 mg) diluted in 1!PBS (pH 7.4) was
adsorbed onto each well of the 96-well plate (Immulon 2HB;
Thermo Life Sciences) overnight at room temperature. The plate
waswashedthreetimesbetweeneachstepwith1!PBS–Tween
(0.05%). After blocking with 100 ml of 1% BSA in PBS for 1 h at
37 8C, 100 ml recombinant human VEGF165 diluted in 1% BSA
in PBS (ranging from 62.5 pg/ml to 4 ng/ml) or protein samples
was added to each well. After incubation for 1 h at 37 8C with
shaking and three washes, 100 ml detection antibody at
0.05 mg/ml was added to each well, and the plate was left for
1 h at 37 8C with shaking. Streptavidin–HRP (100 ml; R&D
Systems)at1:200dilutionin1%BSAinPBSwasadded,theplate
was left at room temperature for 20 min and 100 ml/well
O-phenylenediamine dihydrochloride solution (substrate
reagent pack DY-999; R&D Systems) was added, protected
from light and incubated for 20 min at room temperature.
The reaction was stopped with 50 ml/well 1 M H2SO4, and
absorbance was read immediately in the Opsys MR 96 well
plate reader at 492 nm, with control reading at 460 nm.
H&E staining and follicle counting
Mouse ovaries were ﬁxed in Bouin solution and embedded in
parafﬁn wax, and 5 mm sections were subjected to H&E staining
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selected for follicle counting, and for atretic follicle number,
sections were sampled. Primary, secondary and tertiary follicles
were categorised by using a follicle classiﬁcation developed by
Pedersen & Peters (1968) and Myers et al.( 2 0 0 4 ) .
Immunohistochemistry
Ovary samples from WT, TG mice were ﬁxed with Bouin
solution, while marmoset ovaries were ﬁxed in neutral buffered
formalin, and embedded in parafﬁn. Sections (5 mm) were
mounted onto gelatin/poly-L-lysine-coated glass slides. The
sectionsweredriedontotheslidesina37 8Cincubatorovernight.
Sections were dewaxed in xylene for 15 min and rehydrated
through graded ethanol solutions (100, 90 and 70%, v/v).
Microwave antigen retrieval was performed in 0.01 M sodium
citric buffer (pH 6.0) for 7 min at 95 8C at 800 W followed by
9 min at 120 W. Sections were cooled to room temperature
before being washed twice in deionised water for 5 min each
time. Sections were incubated with freshly prepared 3% (v/v)
hydrogen peroxide (BDH, Poole, UK) diluted in 1!PBS for
5 min, then washed twice for 5 min with 1!PBS and blocked
with 5% (w/v) BSA (Sigma) followed by 1.5% (w/v) normal goat
serum (Vector Laboratories, Peterborough, UK) in 5% (w/v) BSA
for 30 min. The sections were washed twice with 0.05% (v/v)
PBS–Tween at room temperature for 5 min, then incubated with
the primary antibody diluted in 1.5% w/v normal goat serum in
1!PBS. A polyclonal rabbit VEGF antibody (A20 sc152; Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, USA) was used. Tissue
sections were treated with a matched concentration of normal,
afﬁnity-puriﬁed rabbit IgG (Sigma), used as a negative control.
The sections were washed twice in 0.05% (v/v) PBS–Tween, for
5 min each time. The blocking step was repeated as before,
followed by two 5-min washes in 0.05% (v/v) PBS–Tween. All
sections,includingthecontrols,wereincubatedwithbiotinylated
goat anti-rabbit IgG (Vector Laboratories) diluted in 1.5% (w/v)
normal goat serum for 1 h in a humid chamber at room
temperature. Sections were washed twice with 0.05% (v/v)
PBS–Tween, 5 min/wash, then incubated with a pre-prepared
avidin–biotinylated enzyme complete kit (Vector Laboratories)
for 45 min in a humid chamber at room temperature. Again, the
sections were washed twice with 0.05% (v/v) PBS–Tween, 5 min
each time, followed by incubation with 3,30-diaminobenzidine
substrate (Vector Laboratories) to yield a brown-coloured
product. The reaction was stopped by washing twice with
deionised water for 5 min. Sections were counterstained with
Mayer’s haematoxylin (BDH) for 5 min, then differentiated in
water. Sections were dehydrated by passing through increasing
concentrationsofethanol(70,90and100%,v/v)foratleast2 min
each, cleared in xylene for at least 10 min, and permanently
mounted in DPX Mountant for histology. Staining was examined
with a Nikon Eclipse E-400 microscope; images were captured
using a DCN-100 digital imaging system (Nikon Instruments).
For staining of microvessels, 5 mm ovary sections were dried
thoroughly on SuperFrost slides (Fisher Scientiﬁc, Loughbor-
ough, UK). Non-speciﬁc binding was blocked with 5% normal
goat serum in 0.5% PBS–Triton 100 for 1 h and avidin/biotin
blocking reagent (Vector Laboratories) was applied for 15 min
each on sections. Vasculature staining was performed with
incubation with 5 mg/ml biotinylated isolectin B4 (Life Tech-
nologies, Paisley, UK) at 4 8C overnight and washing in 0.5%
PBS–Triton 100 four times each for 5 min followed by 1 h
incubation with 2 mg/ml AlexaFluor 555-conjugated streptavi-
din (Vector Laboratories). After washing, sections were counter
stained with 5 mg/ml Hoechst for 30 min and coverslipped with
Vectashield (Vector Laboratories). Images were analysed with
Leica confocal microscope using a !40 oil objective.
Microvessels stained in red were selected in Photoshop and
MVD (microvessel covering area per unit perimeter of the
follicle or microvascular coverage area/total area % for corpus
lutea) was calculated in ImageJ.
Forpericytestaining,antigenretrievalwasperformedin0.01 M
sodium citrate buffer (pH 6.0), for 7 min at 95 8Ca t8 0 0 W
followed by 9 min at 120 W. Avidin/biotin blocking reagent
(VectorLaboratories)wasappliedfor15 mineachonsectionsand
non-speciﬁcbindingwasblockedwith1%BSA,2%normalhorse
serum in 0.05% PBS–Tween 20 (pH 7.4) for 1 h. Pericyte staining
was performed with incubation with 1:200 anti-NG2 antibody in
blockingsolution(MolecularProbe)at4 8Covernightandwashing
in0.05%PBS–Tween20fourtimeseachfor5 minfollowedby2 h
incubation with 2 mg/ml AlexaFluor 488-conjugated goat anti-
rabbit IgG (Vector Laboratories) in blocking solution. After
washing, sections were counterstained with 5 mg/ml Hoechst
for 30 min and coverslipped with Vectashield (Vector Labora-
tories). Images were analysed with Leica confocal microscope
usinga!40oilobjective.Pericytesstainedingreenwereselected
in Photoshop and pericyte density (pericyte coverage area/total
area %) was calculated in ImageJ (Abramoff et al.2 0 0 4 ).
For cleaved caspase-3 staining, antigen retrieval was per-
formedbybringingslidestoaboilin10 mMsodiumcitratebuffer
(pH6.0)followedbymaintainingatasub-boilingtemperaturefor
10 min. Sections were incubated with freshly prepared 3% (v/v)
hydrogen peroxide in 1!PBS for 5 min. Non-speciﬁc blocking
was achieved by incubation of sections for 1 h with 5% normal
goatserumdilutedinTBS–0.1%Tween20andwithavidinDand
biotin solution each for 15 min. A polyclonal rabbit cleaved
caspase-3 antibody (1:400;(New England Biolabs, Hitchin, UK))
diluted in blocking solution was applied on sections and
incubated overnight at 4 8C. Biotinylated goat anti-rabbit IgG
diluted in blocking solution was then applied for 30 min in a
humid chamber at room temperature. After washing, sections
wereincubatedwitha pre-preparedavidin–biotinylated enzyme
completekitfollowedbyincubationwith3,30-diaminobenzidine
substrate (Vector Laboratories) to yield a brown-coloured
product. The reaction was stopped by washing with deionised
water for 5 min. Sections were counterstained with Mayer’s
haematoxylin (BDH) for 2 min and then differentiated in water.
Sections were dehydrated by passing through increasing
concentrations of ethanol (70, 90 and 100%, v/v) for at least
2 mineach,clearedinxyleneforatleast10 minandpermanently
mounted in DPX Mountant for histology. Staining was examined
with a Nikon Eclipse E-400 microscope; images were captured
using a DCN-100 digital imaging system (Nikon Instruments).
Collection of embryos
Both oviducts from each female mouse at 0.5 dpc
were dissected and transferred into M2 medium in Petri dish.
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gently squeezed out. Embryos were collected with a mouth
pipette and released into M2 medium with hyaluronidase
(10 mg/ml). The number of embryos was counted. Embryos
were washed four times in M2 medium and transferred into
well-equilibrated M16 medium in an incubator. Cells were
maintained in M16 medium in the incubator for 4 days to
blastocyst stage, checked each dayand the number of alive and
dead cells was recorded.
Cycle determination
Ten microlitre of 0.9% NaCl was injected into a female mouse
vagina with a pipette. After pipetting, the solutions were
collected, pipetted onto a clean slide and pulled to form a
smear. After drying at room temperature, a smear was stained
with 10% Giemsa for 5 min, rinsed with tap water, and dried
and viewed under a light microscope. Female cyclic stage was
determined, as shown in Fig. 5. Cycle determinations were
repeated every day for at least two cycles and the number of
days for each cycle was calculated. Four mice were excluded
(two WT and two TG) as cycle time in diestrus was O3 days,
indicating a missed cycle.
Statistical analysis
Figures are given as meanGS.E.M. unless stated; P!0.05 was
regarded as signiﬁcant. Methods of statistical analysis are
included in relevant ﬁgure legend. For single comparisons
t-testswere used with Welch’s correction wherevariances were
signiﬁcantly different, and data normally distributed, or paired
t-test when samples were matched to littermates. Integral data
(e.g. number of embryos), or non-normally distributed data
(determined by Kolmogorov–Smirnoff test) were tested by non-
parametric statistics (Wilcoxon paired or Mann–Whitney
unpaired U-test). For comparison purposes, VEGF expression,
litter size, number of embryos, follicle number and pro-
portions, vessel densities and luteal sizes, and days in cycles
were considered as independent variables. The experimental
units were numbers of mice in TG or WT groups. Frequencies
were compared by a c
2-test (Fisher’s exact test for 2!2 tables).
Power analysis for non-signiﬁcant values was carried out with
G.Power using 80% power as a minimum cut-off.
Supplementary data
This is linked to the online version of the paper at http://dx.doi.
org/10.1530/REP-11-0091.
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